[Skip to Content]
[Skip to Content Landing]

Conference Presentation: Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Trial

In this randomized, double-blind, placebo-controlled, dose-finding adaptive phase 2a/2b trial, treatment with human recombinant alkaline phosphatase did not improve kidney function among critically ill patients with sepsis-associated acute kidney injury (AKI). Peter Pickkers, MD, PhD, of Radboud University Nijmegen Medical Center, the Netherlands, presents findings from the STOP-AKI trial at the European Society of Intensive Care Medicine (ESICM) 31st Annual Congress, LIVES 2018, on October 24 in Paris. Used with permission.

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Close

Name Your Search

Save Search
Close
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
Close